GLP-1 beginner mistakes: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag context, @maicyrobison is likely sharing a list of common beginner mistakes people make when starting a GLP-1 receptor agonist, probably semaglutide or tirzepatide given the #shedrx tag. These videos typically cover things like not eating enough protein, skipping meals and feeling terrible later, not staying hydrated, pushing dose escalations too fast, or ignoring side effects like nausea and gastroparesis symptoms. The format is almost certainly personal experience framed as advice, which is the dominant structure in the #glp1community space. That framing is not inherently wrong, but anecdote-as-guidance has real limits when the drug involved has a clinical titration protocol and documented adverse event profile. Some advice in this genre is genuinely useful. Some of it contradicts prescriber guidance in ways that matter.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced mean weight loss of 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced up to 20.9% weight loss over 72 weeks. Both trials used structured dose escalation schedules, not user-driven titration. The most common adverse events across both trials were gastrointestinal: nausea (44% with semaglutide in STEP 1), vomiting, diarrhea, and constipation. These were dose-dependent and most frequent during escalation phases. Protein intake matters here. A 2023 analysis in Obesity Reviews flagged lean mass loss as a real concern during rapid GLP-1-induced weight loss, particularly without resistance training and adequate dietary protein, typically cited at 1.2 to 1.6 grams per kilogram of body weight.

Where does the social media noise diverge from clinical reality?

The biggest divergence in GLP-1 TikTok content is around dose management. Creators frequently advise staying on a lower dose longer than prescribed if side effects appear, or escalating faster if weight loss stalls. Both impulses are understandable but potentially problematic. Dose escalation schedules in clinical trials were designed around tolerability data, not preference. A second significant issue is the normalization of severe nausea as just part of the process. Nausea that prevents eating or drinking is a clinical signal, not a badge of efficacy. A 2022 paper in Diabetes Care (Davies et al.) noted that GI side effects were the leading cause of discontinuation in real-world semaglutide use. Third, content in this space sometimes conflates compounded semaglutide with FDA-approved brand formulations. They are not equivalent products. Potency, purity, and excipients differ, and the FDA has issued warnings on this point directly.

What should you actually know?

If you are starting a GLP-1 agonist, the most evidence-backed things you can do are follow your prescribed titration schedule, prioritize protein to preserve lean mass, stay hydrated, and report persistent GI symptoms to your prescriber rather than managing them based on TikTok advice. A 2023 clinical review in The Lancet Diabetes and Endocrinology (Rubino et al.) emphasized that behavioral support alongside GLP-1 therapy produces better long-term outcomes than medication alone. Muscle loss during caloric restriction on GLP-1s is real and underappreciated in social media spaces. Resistance training is not optional if you care about body composition. And finally, these medications work best as part of a supervised care plan. A prescriber who knows your full health picture is not interchangeable with a comment section, no matter how large the community.